Key result
Ertugliflozin delivers consistent kidney benefits regardless of baseline heart failure status.
Why the study?
The effects of ertugliflozin on kidney outcomes in patients with and without baseline heart failure were unclear.
Does ertugliflozin improve kidney outcomes in patients with heart failure at baseline?
RCT
Randomized
Does ertugliflozin improve kidney outcomes in patients with heart failure at baseline?
Ertugliflozin provides consistent kidney benefits in patients regardless of baseline heart failure status.
Answers are grounded in this paper and cite their sources.
Ertugliflozin kidney benefits are consistent regardless of baseline heart failure; confirms uniform SGLT2i effects across HF strata in CKD.
Introduction: analysis, the effects of ertugliflozin on kidney outcomes were assessed in analyses stratified by baseline heart failure (HF). Methods: Baseline HF was defined as a history of HF or prerandomization left ventricular ejection fraction ≤45%. Outcomes included estimated glomerular filtration rate (eGFR) over time, total 5-year eGFR slopes and time to first event of a prespecified exploratory kidney composite outcome of sustained ≥40% decrease from baseline eGFR, chronic kidney replacement therapy, or kidney death. All analyses were stratified by baseline HF status. Conclusion: Although patients with HF at baseline had a faster rate of eGFR decline in VERTIS CV, the beneficial effects of ertugliflozin on kidney outcomes did not differ when stratified by baseline HF.
No takes yet. Share an insight, caveat, or question.
Cherney et al. (2023) conducted an RCT in Heart Failure. Ertugliflozin was evaluated on Estimated glomerular filtration rate (eGFR) over time, total 5-year eGFR slopes and time to first event of a prespecified exploratory kidney composite outcome (p=0.22). The beneficial effects of ertugliflozin on kidney outcomes did not differ when stratified by baseline heart failure status.
Synapse has enriched 10 related papers. Consider them for comparative context: